Oncolytic Virus Therapy Market - 2025-2033

November 2025 | 49 pages | ID: OF70EE731E8DEN
DataM Intelligence

Abstracts

Oncolytic Virus Therapy Market reached US$ 27.33 Million in 2024 and is expected to reach US$ 199.98 Million by 2033, growing with a CAGR of 24.90% during the forecast period 2026-2033.

The Oncolytic Virus Therapy Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.

A Oncolytic Virus Therapy Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.

By Drug

• Imlygic*
• Delytact
• Oncorine

By Virus Type

• Herpes Simplex Virus type-1*
• Adenovirus type-5
• Others

By Indication

• Unresectable Melanoma*
• Head and Neck Cancer
• Malignant Glioma

By Distribution Channel

• Hospital Pharmacies*
• Retail Pharmacies

Regional Analysis for Oncolytic Virus Therapy Market:

• North America (U.S., Canada, Mexico)
• Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
• Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
• South America (Colombia, Brazil, Argentina, Rest of South America)
• Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

This Report Covers:

• Go-to-market Strategy.
• Neutral perspective on the market performance.
• Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
• Customized regional/country reports as per request and country level analysis.
• Potential & niche segments and regions exhibiting promising growth covered.
• Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Research Process:

Both primary and secondary data sources have been used in the global Oncolytic Virus Therapy Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Contents

1. MARKET INTRODUCTION AND SCOPE

1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope

2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS

3. MARKET HIGHLIGHTS AND STRATEGIC TAKEAWAYS

3.1. Key Trends and Future Projections
3.2. Snippet by Drug
3.3. Snippet by Virus Type
3.4. Snippet by Indication
3.5. Snippet by Distribution Channel
3.6. Snippet by Region

4. DYNAMICS

4.1. Impacting Factors
  4.1.1. Drivers
    4.1.1.1. Strong Research and Development Pipeline
    4.1.1.2. Rising Cancer Incidence Globally
  4.1.2. Restraints
    4.1.2.1. High Manufacturing Complexity and Cost
    4.1.2.2. Safety and Immunogenicity Concerns
  4.1.3. Opportunity
    4.1.3.1. Combination Therapies with ICIs and Targeted Drugs
    4.1.3.2. Expansion Into New Indications

5. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK

5.1. Market Leaders and Pioneers
  5.1.1. Emerging Pioneers and Prominent Players
  5.1.2. Established Leaders with the Largest Marketing Brand
  5.1.3. Market Leaders with Established Products
5.2. Latest Developments and Breakthroughs
5.3. Regulatory and Reimbursement Landscape
  5.3.1. North America
  5.3.2. Europe
  5.3.3. Asia Pacific
  5.3.4. South America
  5.3.5. Middle East & Africa
5.4. Porter’s Five Forces Analysis
  5.4.1. Bargaining Power of Suppliers
  5.4.2. Bargaining Power of Buyers
  5.4.3. Threat of Substitutes
  5.4.4. Threat of New Entrants
  5.4.5. Competitive Rivalry
5.5. Patent Analysis
  5.5.1. Patent Expiry and Exclusivity
  5.5.2. Key Patent Holders
  5.5.3. Patent Litigations
  5.5.4. Licensing Opportunities
5.6. Unmet Needs and Gaps
5.7. Recommended Strategies for Market Entry and Expansion
5.8. Pricing Analysis and Price Dynamics
  5.8.1. Price Benchmarking vs. Competitors
  5.8.2. Reimbursement Landscape
  5.8.3. Pricing Trends by Region or Segment
  5.8.4. Value-Based Pricing Opportunities
5.9. SWOT Analysis
  5.9.1. Strengths: Internal Advantages
  5.9.2. Weaknesses: Internal Limitations
  5.9.3. Opportunities: External Growth Possibilities
  5.9.4. Threats: External Challenges
5.10. Supply Chain Analysis
  5.10.1. Raw Material Sourcing
  5.10.2. Manufacturing Locations
  5.10.3. Distribution Channels
  5.10.4. Logistics and Transportation
  5.10.5. Supplier Risk Assessment

6. ONCOLYTIC VIRUS THERAPY MARKET, BY DRUG

6.1. Introduction
  6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
  6.1.2. Market Attractiveness Index, By Drug
6.2. Imlygic*
  6.2.1. Introduction
  6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Delytact
6.4. Oncorine

7. ONCOLYTIC VIRUS THERAPY MARKET, BY VIRUS TYPE

7.1. Introduction
  7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Virus Type
  7.1.2. Market Attractiveness Index, By Virus Type
7.2. Herpes Simplex Virus type-1*
  7.2.1. Introduction
  7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Adenovirus type-5
7.4. Others

8. ONCOLYTIC VIRUS THERAPY MARKET, BY INDICATION

8.1. Introduction
  8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  8.1.2. Market Attractiveness Index, By Indication
8.2. Unresectable Melanoma*
  8.2.1. Introduction
  8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Head and Neck Cancer
8.4. Malignant Glioma

9. ONCOLYTIC VIRUS THERAPY MARKET, BY DISTRIBUTION CHANNEL

9.1. Introduction
  9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacies*
  9.2.1. Introduction
  9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacies

10. ONCOLYTIC VIRUS THERAPY MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES

10.1. Introduction
  10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  10.1.2. Market Attractiveness Index, By Region
10.2. North America
  10.2.1. Introduction
  10.2.2. Key Region-Specific Dynamics
  10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
  10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Virus Type
  10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    10.2.7.1. U.S.
    10.2.7.2. Canada
    10.2.7.3. Mexico
10.3. Europe
  10.3.1. Introduction
  10.3.2. Key Region-Specific Dynamics
  10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
  10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Virus Type
  10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    10.3.7.1. Germany
    10.3.7.2. UK
    10.3.7.3. France
    10.3.7.4. Spain
    10.3.7.5. Italy
    10.3.7.6. Rest of Europe
10.4. Asia-Pacific
  10.4.1. Introduction
  10.4.2. Key Region-Specific Dynamics
  10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
  10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Virus Type
  10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    10.4.7.1. China
    10.4.7.2. India
    10.4.7.3. Japan
    10.4.7.4. South Korea
    10.4.7.5. Rest of Asia-Pacific
10.5. South America
  10.5.1. Introduction
  10.5.2. Key Region-Specific Dynamics
  10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
  10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Virus Type
  10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    10.5.7.1. Brazil
    10.5.7.2. Argentina
    10.5.7.3. Rest of South America
10.6. Middle East and Africa
  10.6.1. Introduction
  10.6.2. Key Region-Specific Dynamics
  10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
  10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Virus Type
  10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. COMPETITIVE LANDSCAPE AND MARKET POSITIONING

11.1. Competitive Overview and Key Market Players
11.2. Market Share Analysis and Positioning Matrix
11.3. Strategic Partnerships, Mergers & Acquisitions
11.4. Key Developments in Product Portfolios and Innovations
11.5. Company Benchmarking

12. COMPANY PROFILES

12.1. Top Companies
  12.1.1. Amgen, Inc.*
    12.1.1.1. Company Overview
      12.1.1.1.1. Product Portfolio
      12.1.1.1.2. Product Description
      12.1.1.1.3. Product Key Performance Indicators (KPIs)
    12.1.1.2. Financial Overview
      12.1.1.2.1. Company Revenue
      12.1.1.2.2. Geographical Revenue Shares
      12.1.1.2.3. Revenue Forecasts
    12.1.1.3. Key Developments
      12.1.1.3.1. Mergers & Acquisitions
      12.1.1.3.2. Key Product Development Activities
      12.1.1.3.3. Regulatory Approvals, etc.
      12.1.1.3.4. SWOT Analysis
  12.1.2. Shanghai Sunway Biotech Co., Ltd.
  12.1.3. Daiichi Sankyo Co., Ltd.
  12.1.4. Emerging Players
    12.1.4.1. Oncolytics Biotech Inc.
    12.1.4.2. KaliVir Immunotherapeutics, Inc.,
    12.1.4.3. TILT Biotherapeutics (TILT)
    12.1.4.4. Memgen, Inc.
    12.1.4.5. Genelux Corporation
    12.1.4.6. CG Oncology
    12.1.4.7. Candel Therapeutics, Inc. (LIST NOT EXHAUSTIVE )

13. ASSUMPTIONS AND RESEARCH METHODOLOGY

13.1. Data Collection Methods
13.2. Data Triangulation
13.3. Forecasting Techniques
13.4. Data Verification and Validation

14. APPENDIX

14.1. About Us and Services
14.2. Contact Us